Article

A novel bacterial protease inhibitor adjuvant in RBD-based COVID-19 vaccine formulations increases neutralizing antibodies, specific germinal center B cells and confers protection against SARS-CoV-2 infection

2021-12-09

Abstract excerpt

In this work we evaluated recombinant receptor binding domain (RBD) based vaccine formulation prototypes with potential for further clinical development. We assessed different formulations containing RBD plus Alum, AddaS03, AddaVax or the combination of Alum and U-Omp19: a novel Brucella spp. protease inhibitor vaccine adjuvant. Results show that the vaccine formulation composed of U-Omp19 and Alum as adjuvants h...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 6e245bd8-62b5-59e1-93bc-0b6712e17643
DOI: 10.1101/2021.12.07.471590

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A novel bacterial protease inhibitor adjuvant in RBD-based COVID-19 vaccine formulations increases neutralizing antibodies, specific germinal center B cells and confers protection against SARS-CoV-2 infectionDOI 10.1101/2021.12.07.471590Read

An Overview of Vaccine Development for COVID-19Semantic proximity Read

Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2Semantic proximity Read

Early Real-World Evidence on the Relative SARS-CoV-2 Vaccine Effectiveness of Bivalent COVID-19 Booster Doses: a Narrative ReviewSemantic proximity Read

Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and SafetySemantic proximity Read

Safety, tolerability, and immunogenicity of a new SARS-CoV-2 recombinant Gamma variant RBD-based protein adjuvanted vaccine, used as heterologous booster in healthy adults: a Phase 1 interim reportSemantic proximity Read

SARS-CoV-2 vaccines - the biggest medical research project of the 21st century.Semantic proximity Read

Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2Semantic proximity Read

Development of a Recombinant RBD Subunit Vaccine for SARS-CoV-2Semantic proximity Read

Early real world evidence on the relative SARS-COV-2 vaccine effectiveness of bivalent COVID-19 booster doses: a rapid reviewSemantic proximity Read

Protection of the receptor binding domain (RBD) dimer against SARS-CoV-2 and its variants.Semantic proximity Read

SARS-CoV-2 subunit vaccine adjuvants and their signaling pathwaysSemantic proximity Read

Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concernSemantic proximity Read